English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/123620
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

The Long and Winding Road to Cancer Treatment: The Trail System

AutorPalacios, Carmen ; Yerbes, Rosario ; Sánchez-Pérez, Tania ; Martín-Pérez, Rosa ; Cano-González, Ana ; López-Rivas, Abelardo
Palabras claveTRAIL signaling
Therapeutic potential
Clinical trials
Fecha de publicación2014
EditorBentham Science Publishers
CitaciónCurrent Pharmaceutical Design 20(17): 2819- 2833 (2014)
ResumenActivation of cell surface death receptors of the tumor necrosis factor (TNF) receptor superfamily by the appropriate ligands represents an attractive therapeutic strategy to induce cell death by apoptosis in cancer cells. However, the toxic effects of TNF-alpha and CD95/Fas ligand (FasL) in normal tissues have significantly hampered the clinical application of these ligands in cancer treatment. TNFrelated apoptosis-inducing ligand (TRAIL/APO-2L), another member of the TNF family, has been shown to induce apoptosis selectively in many tumor cell lines. Interestingly, TRAIL treatment also results in significant growth suppression of TRAIL-sensitive human cancer xenografts in mice and nonhuman primates. At the same time, recombinant TRAIL and agonistic TRAIL receptor antibodies show no significant cytotoxicity in these studies. Despite some adverse effects of certain TRAIL preparations, activation of proapoptotic TRAIL receptors represents a promising approach in cancer therapy. Herein we review what is known about proapoptotic TRAIL signaling, the role of intracellular survival pathways in the regulation of resistance to TRAIL and the activation of non-apoptotic signaling by TRAIL. We also discuss the role of the TRAIL system in tumorigenesis and the results of clinical trials with recombinant TRAIL and various TRAIL receptor agonistic antibodies, either as monotherapy or in combination with targeted or conventional chemotherapy
Versión del editorhttp://dx.doi.org/10.2174/13816128113199990588
Identificadoresdoi: 10.2174/13816128113199990588
issn: 1873-4286
Aparece en las colecciones: (CABIMER) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Mostrar el registro completo

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.